RECENT DEVELOPMENTS IN THE DIAGNOSIS AND TREATMENT OF HEPATITIS: A GLOBAL PERSPECTIVE

Аннотация

Hepatitis, an inflammation of the liver primarily caused by viral infections, remains a major public health concern worldwide. This article reviews the current understanding of hepatitis types A to E, emphasizing their epidemiology, pathogenesis, and therapeutic approaches. We examine recent developments in diagnostic techniques, including molecular assays and imaging, as well as innovations in antiviral therapies. The introduction of direct-acting antivirals (DAAs) has significantly improved outcomes for hepatitis C patients. Global vaccination efforts have reduced the incidence of hepatitis B, though challenges remain in low-income countries. Despite progress, gaps persist in early diagnosis, access to treatment, and long-term disease monitoring. This review highlights key advancements and identifies areas where further research and investment are needed to control and eventually eliminate hepatitis as a global threat. Keywords: Hepatitis, antiviral therapy, liver disease, global health, viral hepatitis, DAAs. 1. Introduction Hepatitis affects over 350 million people globally, contributing significantly to liver- related morbidity and mortality. It is caused by several viral agents—hepatitis A, B, C, D, and E viruses—each with distinct modes of transmission, disease progression, and treatment options. Hepatitis B and C are the most common chronic forms, often leading to liver fibrosis, cirrhosis, and hepatocellular carcinoma. This review explores recent trends in hepatitis research, focusing on diagnostics, treatment, and prevention strategies. 2. Epidemiology Estimated Cases Main Transmission Regions Most Type (Million) Route Affected Fecal-oral Hepatitis A 114 (contaminated Africa, South Asia food/water) Blood, sexual Sub-Saharan Hepatitis B 296 contact, mother-to- Africa, East Asia child Blood (especially Central Asia, Hepatitis C 58 unsafe injections) Eastern Europe Requires HBV co- Africa, Eastern Hepatitis D 12 infection Europe South Asia, East Hepatitis E 20 Fecal-oral Africa 3. Pathophysiology Hepatitis viruses cause liver inflammation through immune-mediated cell injury. Chronic infections, particularly hepatitis B and C, can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. The persistence of viral antigens in hepatocytes contributes to ongoing immune activation and fibrosis. 1073 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5 4. Advances in Diagnosis Method Target Virus Description Advantages ELISA All types Detects antibodies Cost-effective, or antigens widely used PCR B, C, D Detects viral High sensitivity RNA/DNA and specificity Transient All types Measures liver Non-invasive Elastography stiffness alternative to biopsy Liver Biopsy All types Histological Invasive but examination of comprehensive liver tissue 5. Current and Emerging Treatments Virus Approved Cure Rate / Viral Vaccine Available Treatments Suppression Hepatitis A Supportive care Self-limited Yes Hepatitis B Tenofovir, Long-term Yes Entecavir suppression Hepatitis C Sofosbuvir, >90% (12-week No Ledipasvir, course) Glecaprevir Hepatitis D Pegylated <30% sustained No (HBV vaccine Interferon-alpha response protective) Hepatitis E Supportive care, Self-limited in Limited (China Ribavirin (severe most cases only) cases) 6. Challenges and Future Directions Despite effective antiviral agents, significant gaps remain: - Late diagnosis due to asymptomatic early stages - Poor access to diagnostics and treatment in low-income countries - Lack of vaccines for hepatitis C and E - Limited treatment efficacy for hepatitis D Future priorities: - Scale-up of affordable point-of-care diagnostics - Expanded DAA availability in LMICs - Clinical trials for therapeutic vaccines - Integration of hepatitis screening into primary care 7. Conclusion Effective diagnostic tools and antiviral treatments have changed the landscape of hepatitis care, particularly for hepatitis C. However, hepatitis remains a global health burden due to unequal access to healthcare services, limited public awareness, and gaps in prevention strategies. Global cooperation, policy change, and innovation are essential to meet WHO’s goal of hepatitis elimination by 2030. 1074 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5